{"entity":{"id":"nct05874414","kind":"trial","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","aka":[],"tldr":"A phase 1/2 trial of Trametinib in biliary tract cancer, run by Genfit, now recruiting.","summary":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma is a phase 1/2 interventional study registered as NCT05874414 by Genfit, with 98 participants planned, started 2023-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: GNS561 + Trametinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05874414","url":"https://clinicaltrials.gov/study/NCT05874414"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["trametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05874414","phase":"1/2","setting":"Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma","sponsor":"Genfit","enrolled":98,"outcomes":[]},"route":"/trials/nct05874414/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"drug":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}]}}